Le Lézard
Classified in: Health
Subject: SVY

The chemotherapy treatment market will register a CAGR of nearly 3% by 2023


NEW YORK, May 22, 2019 /PRNewswire/ --

About this market

The recent approvals of chemotherapeutics to treat cancer is one of the key factors expected to trigger the chemotherapy treatment market during the forecast period. With the rising prevalence of cancer, the demand for chemotherapeutics agents is increasing. The market has witnessed recent approvals of chemotherapeutics agents such as TECENTRIQ by regulatory authorities in different regions. TECENTRIQ in combination with carboplatin and etoposide is being used for first-line treatment of adult patients with extensive-stage, small-cell lung cancer. This will boost the chemotherapy treatment market growth during the forecast period. Analysts have predicted that the chemotherapy treatment market will register a CAGR of nearly 3% by 2023.



Read the full report: https://www.reportlinker.com/p05777280/?utm_source=PRN



Market Overview

Availability of drugs to treat the side-effects of chemotherapy

The drugs used in chemotherapy for cancer treatment have several side-effects such as vomiting and nausea, hypersensitivity reactions, and neutropenia. Hence, the availability of drugs to treat these side-effects will drive the growth of the market during the forecast period.

Emerging targeted therapies

The market has witnessed the development and approval of targeted therapies to treat different cancers, such as prostate cancer, lung and bronchus cancer, and thyroid cancer. This may pose a challenge to the global chemotherapy treatment market.

For the detailed list of factors that will drive and challenge the growth of the chemotherapy treatment market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated with the presence of a few market players. Several vendors in the market are focusing on the development of combination therapies with chemotherapy drugs along with targeted therapies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Read the full report: https://www.reportlinker.com/p05777280/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 06:15
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Exciting technical...

at 06:10
Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The 2-year grant...

at 06:08
Aesthetic Management Partners LLC, a manufacturer of skin-based solutions and a provider of energy-based devices announces its collaboration with Croma (Croma-Pharma® GmbH), a global player in the minimally invasive aesthetics market and a leading...

at 06:05
The 2023 U.S. soybean field trials conducted by Texas Crop Science (TCS) demonstrated an average yield increase of 21% in soybean lines incorporating the TCS yield trait. This breakthrough in performance would generate approximately $121 per acre in...

at 06:05
3EO Health, a "Point of Life" diagnostics company focused on the development of high-performing low-cost molecular diagnostics, is excited to announce the next step in their quest to make molecular testing affordable. Today, the company has published...

at 06:05
Zura Bio Limited ("Zura Bio") a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights. The Company has also...



News published on and distributed by: